Abstract

JEVEY GONZALEZ, Aidelian et al. Design and validation of an inmunoenzymatic system (ELISA) that quantifies lipoprotein(a) in human seru. AMC [online]. 2005, vol.9, n.1, pp.42-51. ISSN 1025-0255.

Lipoprotein (a) is considered a cardiovascular risk factor. High blood concentrations of this lipoprotein are associated with an increased incidence and severety of atherosclerosis. Assessment of the cardiovascular risk associated with Lp(a) is carried out on the bases of plasmatic concentrations of the said lipoprotein. Serum concentrations of this lipoprotein has been measured by different methods, but inmunoenzymatic essays ELISA have had more application in this respect. In this work, design and validation of an indirect, sandwich type ELISA system validation was performed according to the proposed parameters by the European Committee for Clinical laboratory Standard. Among these parameters, the following are applied to our system: calibration curve, unpreciseness (within rum and between rum) determination of Lp(a) in the serum of patients.

Keywords : DRUG DESIGN; ENSYME-LINKED INMUNOSORBENT ASSAY; LIPOPROTEINS.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )